HK1158206A1 - Fluorescent regulators of rassf1a expression and human cancer cell proliferation rassf1a - Google Patents

Fluorescent regulators of rassf1a expression and human cancer cell proliferation rassf1a

Info

Publication number
HK1158206A1
HK1158206A1 HK11112766.4A HK11112766A HK1158206A1 HK 1158206 A1 HK1158206 A1 HK 1158206A1 HK 11112766 A HK11112766 A HK 11112766A HK 1158206 A1 HK1158206 A1 HK 1158206A1
Authority
HK
Hong Kong
Prior art keywords
rassf1a
expression
group
heterogroup
aryl group
Prior art date
Application number
HK11112766.4A
Other languages
English (en)
Inventor
Milton L Brown
Kathryn D Sheikh
Mikell Paige
Partha Banerjee
Shankar Jagadeesh
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of HK1158206A1 publication Critical patent/HK1158206A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Electroluminescent Light Sources (AREA)
HK11112766.4A 2008-08-15 2011-11-24 Fluorescent regulators of rassf1a expression and human cancer cell proliferation rassf1a HK1158206A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18905908P 2008-08-15 2008-08-15
PCT/US2009/004681 WO2010019271A1 (en) 2008-08-15 2009-08-14 Fluorescent regulators of rassf1a expression and human cancer cell proliferation

Publications (1)

Publication Number Publication Date
HK1158206A1 true HK1158206A1 (en) 2012-07-13

Family

ID=41279343

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11112766.4A HK1158206A1 (en) 2008-08-15 2011-11-24 Fluorescent regulators of rassf1a expression and human cancer cell proliferation rassf1a

Country Status (10)

Country Link
US (1) US10457639B2 (xx)
EP (2) EP2484666A1 (xx)
JP (2) JP2012500197A (xx)
CN (1) CN102186820B (xx)
AT (1) ATE547403T1 (xx)
AU (1) AU2009282451B2 (xx)
BR (1) BRPI0917411A2 (xx)
CA (1) CA2734225A1 (xx)
HK (1) HK1158206A1 (xx)
WO (1) WO2010019271A1 (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
JP5925701B2 (ja) 2010-03-08 2016-05-25 モンサント テクノロジー エルエルシー 植物における遺伝子調節のためのポリヌクレオチド分子
US8637679B2 (en) 2011-03-11 2014-01-28 Council Of Scientific And Industrial Research Process for the isolation of organic compounds useful for the treatment of cancer
MX343072B (es) 2011-09-13 2016-10-21 Monsanto Technology Llc Metodos y composiciones para controlar malezas.
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
UA116089C2 (uk) 2011-09-13 2018-02-12 Монсанто Текнолоджи Ллс Спосіб та композиція для боротьби з бур'янами (варіанти)
CN109997852A (zh) 2011-09-13 2019-07-12 孟山都技术公司 用于杂草控制的方法和组合物
AU2012308660B2 (en) 2011-09-13 2017-05-25 Monsanto Technology Llc Methods and compositions for weed control
AU2012308686B2 (en) 2011-09-13 2018-05-10 Monsanto Technology Llc Methods and compositions for weed control
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
CN104619843B (zh) 2012-05-24 2020-03-06 A.B.种子有限公司 用于使基因表达沉默的组合物和方法
EP2941488B1 (en) 2013-01-01 2023-03-22 Monsanto Technology LLC Methods of introducing dsrna to plant seeds for modulating gene expression
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
UY35385A (es) 2013-03-13 2014-09-30 Monsanto Technology Llc ?métodos y composiciones para el control de malezas?.
BR112015023051A2 (pt) 2013-03-13 2017-11-14 Monsanto Technology Llc método para controle de ervas daninhas, composição herbicida, cassete de expressão microbiano e método de produção de polinucleotídeo
US20160015743A1 (en) * 2013-03-15 2016-01-21 Rush University Medical Center Methods for treating cancer
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
JP6668236B2 (ja) 2013-07-19 2020-03-18 モンサント テクノロジー エルエルシー Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法
AU2014341879B2 (en) 2013-11-04 2020-07-23 Beeologics, Inc. Compositions and methods for controlling arthropod parasite and pest infestations
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
AR099092A1 (es) 2014-01-15 2016-06-29 Monsanto Technology Llc Métodos y composiciones para el control de malezas utilizando polinucleótidos epsps
CN106413390B (zh) 2014-04-01 2019-09-27 孟山都技术公司 用于控制虫害的组合物和方法
US10988764B2 (en) 2014-06-23 2021-04-27 Monsanto Technology Llc Compositions and methods for regulating gene expression via RNA interference
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
RU2754955C2 (ru) 2014-07-29 2021-09-08 Монсанто Текнолоджи Ллс Композиции и способы борьбы с насекомыми-вредителями
EP3256589B1 (en) 2015-01-22 2021-12-22 Monsanto Technology LLC Compositions and methods for controlling leptinotarsa
UY36703A (es) 2015-06-02 2016-12-30 Monsanto Technology Llc Composiciones y métodos para la administración de un polinucleótido en una planta
WO2016196782A1 (en) 2015-06-03 2016-12-08 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
US10173978B2 (en) 2015-08-05 2019-01-08 Georgetown University Small molecule androgen receptor inhibitors and methods of use thereof
CN110785166A (zh) * 2017-06-12 2020-02-11 宫田升平 抗癌药及其用途
CN107266356B (zh) * 2017-07-25 2020-06-26 山西省生物研究院有限公司 一种作为自分泌运动因子抑制剂的咔唑类化合物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2235815A1 (de) * 1972-07-21 1974-01-31 Bayer Ag Polyazofarbstoffe
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
GB9215361D0 (en) 1992-07-20 1992-09-02 Wellcome Found Heterocyclic compounds
ATE225334T1 (de) * 1993-07-26 2002-10-15 Eisai Co Ltd Sulfonamide und sulfonsäure-ester mit je einem trizyclischen heteroring
JP3690825B2 (ja) * 1993-07-26 2005-08-31 エーザイ株式会社 三環式ヘテロ環含有スルホンアミドおよびスルホン酸エステル誘導体
CA2186412A1 (en) * 1995-10-31 1997-05-01 Katherine S. Takaki Ethylamino carbazole melatonergic agents
PT1042305E (pt) 1997-12-22 2005-10-31 Bayer Pharmaceuticals Corp Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
AU3840000A (en) * 1999-04-20 2000-11-02 Meiji Seika Kaisha Ltd. Tricyclic compounds
EP1238973A4 (en) 1999-12-16 2003-01-22 Asahi Chemical Ind NEW SUBSTITUTED TRICYCLIC COMPOUNDS
AU2001252575A1 (en) 2000-04-28 2001-11-12 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
JP4224566B2 (ja) * 2000-12-18 2009-02-18 株式会社医薬分子設計研究所 炎症性サイトカイン産生遊離抑制剤
WO2002060867A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
WO2002074306A1 (fr) 2001-03-19 2002-09-26 Asahi Kasei Kabushiki Kaisha Remedes pour la steatose hepatique
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
WO2006002908A1 (en) 2004-06-29 2006-01-12 Jadolabs Gmbh Carbazole-derived pharmaceutical compositions
EP1778636B1 (en) 2004-08-18 2007-12-19 Ciba SC Holding AG Oxime ester photoinitiators
ITMI20051523A1 (it) * 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
DE112006002340T5 (de) 2005-09-01 2008-07-17 Council Of Scientific And Industrial Research Arzneimittel, verwendbar zur Behandlung von Prostatakrebs
CN1807413B (zh) * 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
JP2009511562A (ja) * 2005-10-13 2009-03-19 オーキッド リサーチ ラボラトリーズ リミティド ｐＳＴＡＴ３／ＩＬ−６インヒビターとしての新規ヘテロ環式化合物
WO2008051523A2 (en) * 2006-10-23 2008-05-02 Georgetown University Carbazole derivatives useful as medicaments in cancer therapy
IL186935A0 (en) * 2006-10-31 2008-02-09 Veridex Llc Prostate cancer field effect analysis methods and kits
CA2710520A1 (en) * 2007-12-28 2009-07-09 John Wayne Cancer Institute Use of methylation status of mint loci and tumor-related genes as a marker for melanoma and breast cancer
KR101673621B1 (ko) 2008-03-24 2016-11-07 노파르티스 아게 아릴술폰아미드-계 매트릭스 메탈로프로테아제 억제제

Also Published As

Publication number Publication date
JP2014148545A (ja) 2014-08-21
WO2010019271A8 (en) 2011-03-31
CN102186820B (zh) 2013-08-28
JP2012500197A (ja) 2012-01-05
BRPI0917411A2 (pt) 2015-12-01
EP2323982B1 (en) 2012-02-29
EP2323982A1 (en) 2011-05-25
AU2009282451B2 (en) 2014-02-13
US10457639B2 (en) 2019-10-29
CA2734225A1 (en) 2010-02-18
US20110152339A1 (en) 2011-06-23
EP2484666A1 (en) 2012-08-08
AU2009282451A1 (en) 2010-02-18
CN102186820A (zh) 2011-09-14
WO2010019271A1 (en) 2010-02-18
ATE547403T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
HK1158206A1 (en) Fluorescent regulators of rassf1a expression and human cancer cell proliferation rassf1a
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
WO2010000364A8 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
HK1115590A1 (en) Triazolophthalazines
EA201390550A1 (ru) Способы ингибирования пролиферации клеток в egfr-стимулируемых злокачественных опухолях
DE502005002697D1 (de) Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs
CU24269B1 (es) 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
TW200942552A (en) Combination therapy with c-Met and HER antagonists
EA201000558A1 (ru) Производные имидазола
TNSN08278A1 (en) Triazolopyridazines as tyrosine kinase modulators
CL2012000913A1 (es) Uso de una combinacion farmaceutica de compuestos especificos derivados de 4-morfolintieno[3,2-d]pirimidina con 3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil)(3-hidroxi-3-((2s)piperidin-2-il)azetidin-1-il)metanona para tratar localmente un tumor solido avanzado o metastasico.
MX2011011488A (es) Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina.
TW200730532A (en) Camptothecin derivatives as chemoradiosensitizing agents
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
MX2010007927A (es) Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina.
ATE527998T1 (de) Illudin-analoga als krebsmittel
WO2013192423A3 (en) Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
TN2009000389A1 (en) Pyrido [2,3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
ATE443717T1 (de) Metastin derivate und ihre verwendung
CY1123161T1 (el) Παραγωγα δι(φαινυλοπροπανοειδους) γλυκερολης για τη θεραπεια του καρκινου
MX2007006090A (es) 2-metilen-19-nor-(20r)-1a-hidroxi-bishomopregnacalciferol.
TW200605885A (en) Multicyclic lonidamine analogs
IL198465A0 (en) Triazabenzo[e]azulene derivatives for the treatment of tumors
CA2378187A1 (en) Methods for treating therapy-resistant tumors
GB2459808A (en) Novel benzothiazole and benzoxazole linked pyrrolo (2,1-C) (1,4) benzodiazepine hybrids as novel antitumour agents and process for the preparation thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170814